Saturday, November 14, 2026

HANG SENG INDEX Went Up By Over 3% In The Last 5 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

HANG SENG INDEX Went Up By Over 3% In The Last 5 Sessions

(VIANEWS) - HANG SENG INDEX (HSI) has been up by 3.04% for the last 5 sessions. At 22:08 EST on Monday, 5 June, HANG SENG INDEX (HSI) is $19,115.24.

Concerning HANG SENG INDEX's yearly highs and lows, it's 30.95% up from its 52-week low and 15.8% down from its 52-week high.

Volatility

HANG SENG INDEX's last week, last month's, and last quarter's current intraday variation average was a positive 0.65%, a negative 0.30%, and a positive 1.20%, respectively.

HANG SENG INDEX's highest amplitude of average volatility was 2.03% (last week), 1.28% (last month), and 1.20% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HANG SENG INDEX's is considered to be oversold (<=20).

News about

  • Nasdaq 100 signal: continues to see impulsive move higher - 05 June 2023. According to DailyForex on Monday, 5 June, "Potential signal: I believe that the NASDAQ 100 will continue to see buyers jump into it, at least until the bubble pops. ", "Because of this, for a short-term trade I like the idea of buying the NASDAQ 100 on tips, especially if I can get involved somewhere near the 14,300 level. "

More news about HANG SENG INDEX (HSI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com